Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib

PaperCitations, authors & open-access status

Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 157 citations, 2014 year and bronze oa status.

157
Citations
2014
Year
bronze
OA Status

Related on ScholarIQ

Maxime Ronot
Author
The Oncologist
Journal
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Hepatocellular Carcinoma Treatment and Prognosis
Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Topic
Liver Disease Diagnosis and Treatment
Topic
470M+ articles · free account